Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol

Pharmacological Research

Volumn 48, Issue 4, 2003, Pages 383-387

  Panchagnula, Ramesh ^a   Sancheti, Pavankumar ^a   Rungta, Shradha ^a   Agrawal, Shrutidevi ^a   Kaul, Chaman Lal ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioavailability; Fixed dose combination; Isoniazid; Pyrazinamide; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STANDARD; WORLD HEALTH ORGANIZATION;

EID: 0041666484     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00175-0     Document Type: Article

References (11)

1. Blomberg B., Spinaci S., Fourie B., Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 79:2001;61-68.
2. Laing R, Fourie B, Ellard G, Sesay, M, Spinaci S, Blomberg B, Bryant D. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva, Tuesday, April 27, 1999. World Health Organization, Geneva, WHO/CDS/CPC/TB/99.267; 1999.
3. Pillai G., Fourie P.B., Padayatchi N., Onyebujoh P., McIlleron H., Smith P., Gabriels G. Recent bioequivalence studies on fixed dose combination antituberculosis drug formulations available on the global market. Int. J. Tuberc. Lung Dis. 3(Suppl.):1999;S309-S316.
4. Fox W. Drug combinations and the bioavailability of rifampicin. Tuberculosis. 71:1990;241-245.
5. International Union Against Tuberculosis and Lung Disease/World Health Organization. The promise and reality of fixed dose combinations with rifampicin. Tuberc Lung Dis 1994;75:180-1.
6. Fourie B, Pillai G, McIlleron H, Smith P, Panchagnula R, Ellard G. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol), World Health Organization, WHO/CDS/TB/99.274; 1999.
7. Agrawal S., Kaul C.L., Panchagnula R. Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form. Pharmazie. 56:2001;636-639.
8. Hauschke D., Steinijans V.W., Diletti E.A. Distribution free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 28:1990;72-78.
9. Panchagnula R., Kaur K.J., Singh I., Kaul C.L. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Int. J. Tuberc. Lung Dis. 3(Suppl):1999;S336-S342.
10. Ritshchel WA. Handbook of basic pharmacokinetics including clinical applications. 4th ed. Hamilton: Drug Intelligence Publications Inc.; 1992. p. 187-212.
11. McIlleron H., Gabriels G., Smith P.J., Fourie P.B., Ellard G.A. The development of a standardized screening protocol for the in vivo assessment of rifampicin bioavailability. Int. J. Tuberc. Lung Dis. 3(Suppl):1999;S329-S335.